RFC
TCRT icon

Russell Frank Company’s Alaunos Therapeutics TCRT Stock Holding History

Russell Frank Company’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-27
Closed -$34K – 3032
2015
Q4 		$34K Hold
27
– – ﹤0.01% 2921
2015
Q3 		$37K Sell
27
-402
-94% -$663K ﹤0.01% 2926
2015
Q2 		$772K Sell
429
-191
-31% -$297K ﹤0.01% 2430
2015
Q1 		$1M Buy
+620
New +$919K ﹤0.01% 2144
2013
Q4 		– Sell
-2
Closed -$1K – 3037
2013
Q3 		$1K Sell
2
-1
-33% -$451 ﹤0.01% 3400
2013
Q2 		$1K Buy
+3
New +$833 ﹤0.01% 3255

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Russell Frank Company's TCRT Position: Q1 2016 in Review

Russell Frank Company sold out of Alaunos Therapeutics (TCRT) in Q1 2016, closing a stake of 27 shares — an estimated $34K sold.

Russell Frank Company first reported a position in TCRT in Q2 2013 and held it in 6 quarters. The position peaked at $1M in Q1 2015. 143 funds tracked by Wall St. Rank hold TCRT as of Q1 2016.

  • Russell Frank Company reported no remaining Alaunos Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Russell Frank Company sold 27 Alaunos Therapeutics shares in Q1 2016, an estimated $34K.
  • Russell Frank Company first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 6 quarters.
  • Russell Frank Company's Alaunos Therapeutics position peaked at $1M in Q1 2015.
  • 143 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.